svnt: <<More telling is the open-label extension trial showing subjects on pegloticase resulted in 2 APTC and 7 non-APTC cardiovascular events whereas again there was none in the placebo arms.>>
you are probably right about the FDA's ultimate response, but how telling is the open-label comparison when all patients except two are in the treatment arm?
Market Data 
Markets 
AI
